GLP-1 Access in New Zealand: What's Available and What It Costs

Wegovy and Mounjaro have NZ approval for weight management but are not publicly funded. That is the practical starting point for private access, checked on 6 September 2026. 1

Ozempic needs a separate explanation: Medsafe records approval but lists the checked NZ presentation as 'Not available'. Approval is not the same as routine supply. 2

This guide covers access, costs and preparation. It is educational, not a recommendation to start, switch or stop medication. Prescribing decisions belong with your treating clinician.

What is currently available

Keep four questions separate: Is the product approved? Is your intended use approved? Can a pharmacy supply it? Is it funded? A yes to one does not answer the others. 1 2

• Wegovy, semaglutide: a weekly injection approved for chronic weight management, including maintenance. 3
• Mounjaro, tirzepatide: a weekly dual GIP/GLP-1 receptor agonist approved for adult type 2 diabetes and chronic weight management. 4
• Ozempic, semaglutide: approved for diabetes-related indications, not weight management. Using it specifically for weight loss is outside its approved indication, or off-label. 2
• Saxenda, liraglutide: a daily injection approved for weight management. It should not be confused with the diabetes brand Victoza. 5 1

For adults, Wegovy and Mounjaro's weight-management indications generally require an initial BMI of at least 30, or at least 27 with a weight-related condition. 3 4

These are product indication criteria, not a complete assessment of your health or an entitlement to treatment. Ask your prescriber which indication applies to you. 3 4

For supply, ask the pharmacy about the exact brand, strength and presentation on your prescription. Do not assume an imported product has the same status as a listed NZ presentation.

For more brand-specific context, see Ozempic in New Zealand.

Pharmac funding: the current picture

Pharmac funds dulaglutide, branded Trulicity, and liraglutide, branded Victoza, for eligible people with type 2 diabetes. This is not funding for weight management alone. 1

Access widened on 1 September 2026. Ethnicity and cardiovascular or kidney-risk requirements were removed, but blood-glucose and prior-treatment conditions remain. 6

For these funded GLP-1 medicines, the criteria retain an HbA1c target of 53 mmol/mol or less not being achieved despite specified medicines for at least six months, where clinically appropriate. 6

Those medicines are empagliflozin, metformin and vildagliptin. Combination-funding restrictions also remain, with an exception involving empagliflozin for heart failure. 6

This is why diabetes diagnosis alone does not settle eligibility. Ask your prescriber to check the current Special Authority criteria against your treatment history. 6

Wegovy is on Pharmac's Options for Investment list. That is not a funding commitment or a promised start date. Do not build your budget around an assumed subsidy. 1

Private prescription: what it actually costs

The following NZ Online Chemist prices were listed on 6 September 2026. They are a retailer snapshot, not a national average or an endorsement. 7

These listings cover four weekly doses, not a calendar month. Prices can differ by strength and pharmacy; an increase in dose does not necessarily mean an increase in price. 7

For a simple budgeting illustration, NZ$500 every four weeks is NZ$6,500 over 52 weeks. That assumes an unchanged price throughout, not a particular starting or maintenance regimen.

Before committing, ask for a written estimate covering:

• The prescribed starting strength and possible later strengths.
• Initial consultation, follow-up and repeat-prescription fees.
• Any separate dispensing, needle or delivery charges.
• Any tests your clinician recommends and whether charges apply.
• Who to contact if your prescribed strength cannot be supplied.

Ask what happens if cost becomes difficult. Discuss alternatives and review arrangements before a financial problem becomes an unplanned interruption.

If a quote involves an imported or compounded product, ask the pharmacist to explain exactly what it is, its approval status and why it is being offered. Do not compare headline prices without that context.

Access pathways

Your GP is a sensible first contact for an assessment, not simply a prescription request. Bring an up-to-date medicines list and mention care received elsewhere rather than assuming one record contains everything.

Ask whether your GP can oversee treatment or whether specialist input would help. Endocrinology or weight-management expertise may be useful when your care is complex; ask about referral costs and waiting times.

Telehealth is another consultation format, not an exemption from prescribing standards. Doctors must have adequate knowledge of your condition and suitable follow-up arrangements. 8

The Medical Council also expects consideration of whether an in-person assessment or examination is needed. Remote care is not automatically poor care, and face-to-face care is not automatically coordinated. 8

Before choosing a service, ask who reviews side effects, who handles urgent questions, how records reach your usual clinician and what happens if the original prescriber is unavailable. 8

The conversation to have with your GP

Use the appointment to agree on a plan. A useful checklist is:

• Suitability: which medicine and indication fit my situation, and what alternatives should we discuss?
• Medical history: do previous pancreatitis, severe digestive problems, kidney disease or diabetes-related eye problems change the assessment? 3 4
• Pregnancy planning: what should I know about pregnancy, breastfeeding and contraception before treatment? 3 4
• Other medicines: do insulin or sulfonylureas increase my risk of low blood glucose, and who will manage any changes? 4
• Dose escalation: what is my prescribed schedule, and whom should I contact if I cannot tolerate it?
• Monitoring: which checks matter for me, such as weight, blood pressure, HbA1c or lipids, and when will we review them?
• Expectations: what would a useful response look like over six to twelve months, and how will we assess benefit beyond weight?
• Practical use: can someone demonstrate the pen and explain storage, missed doses and travel arrangements?
• Longer-term care: when will we review affordability, treatment continuation and any proposed change?

Contraindications and precautions are not interchangeable. Ask your clinician to use the current NZ information for the specific product rather than applying an overseas class-wide checklist. 3 4

Side effects and what to plan for

Nausea, vomiting, diarrhoea, constipation and reflux can occur. Some symptoms ease with time, but persistent symptoms deserve review rather than simply being accepted as the price of treatment. 9

Gallbladder problems and pancreatitis are also recognised concerns. Injection-site reactions can occur. Read the leaflet for your own medicine rather than assuming every product has an identical profile. 3 4

Seek urgent medical assessment for severe, persistent abdominal pain, especially if it reaches your back. Trouble breathing or swelling of the face or throat needs emergency help. 9

Contact your clinician promptly if vomiting prevents you keeping fluids down. Digestive side effects can cause dehydration and affect kidney function. 4

Tell the team before an operation or procedure involving sedation that you use this medicine. Ask them for individual instructions rather than changing treatment yourself. 3

Why nutrition belongs alongside the prescription

Reduced food intake can make adequate nourishment harder. Plan for protein, dietary variety and fluids, rather than treating the smallest possible intake as the goal. 10

Weight loss can include lean tissue as well as fat. Lean mass is not the same as skeletal muscle, so a lean-mass change should not automatically be labelled muscle loss. 10

An appropriate protein intake and resistance training support muscle preservation, but neither guarantees it. GLP-1-specific nutrition evidence still has gaps. 10

Practical preparation can include:

• Keeping manageable protein foods available, such as yoghurt, eggs, tofu, fish or beans.
• Planning smaller meals if large portions are uncomfortable.
• Maintaining strength training suited to your ability and symptoms.
• Seeking dietitian input if eating becomes persistently difficult. 10

For detail, see GLP-1 nutrition strategy and muscle preservation and monitoring.

Longer-term treatment, maintenance and support

Do not assume treatment must end when a weight target is reached. Ongoing treatment may be needed, with benefits, side effects, cost and preferences reviewed together. 11

In the STEP 1 extension, participants previously receiving semaglutide regained about two-thirds of their lost weight, on average, during the year after withdrawal. 11

The extension included 327 participants, and structured lifestyle support also ended. It did not test tapering or whether a particular coaching programme prevents regain. 11

The result supports planning for follow-up, not blaming people for inadequate habits. Nutrition and exercise remain useful, but maintenance after withdrawal cannot be promised. 10 11

Agree on review appointments and who to contact if appetite, weight or glucose management becomes difficult. Any decision to continue, change or discontinue medication belongs with your prescriber.

Inception Nutrition supports meal planning, nutrition habits and training alongside prescribed care. We do not choose medicines or advise on dose escalation or discontinuation, and we do not guarantee a body-composition outcome.

If you want support with that practical work, explore nutrition coaching. For further reading, see what happens after stopping a GLP-1.